WO2006047869A1 - Systeme de tests immunodiagnostiques jetables - Google Patents

Systeme de tests immunodiagnostiques jetables Download PDF

Info

Publication number
WO2006047869A1
WO2006047869A1 PCT/CA2005/001677 CA2005001677W WO2006047869A1 WO 2006047869 A1 WO2006047869 A1 WO 2006047869A1 CA 2005001677 W CA2005001677 W CA 2005001677W WO 2006047869 A1 WO2006047869 A1 WO 2006047869A1
Authority
WO
WIPO (PCT)
Prior art keywords
test system
surface area
test
layer
proteins
Prior art date
Application number
PCT/CA2005/001677
Other languages
English (en)
Inventor
Uma Mahesh Babu
Original Assignee
International Bio-Therapeutic Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Bio-Therapeutic Research Inc. filed Critical International Bio-Therapeutic Research Inc.
Priority to AP2007004015A priority Critical patent/AP2007004015A0/xx
Priority to AU2005301045A priority patent/AU2005301045B2/en
Priority to CN200580045347.7A priority patent/CN101133326B/zh
Priority to CA002585695A priority patent/CA2585695C/fr
Priority to MX2007005180A priority patent/MX2007005180A/es
Priority to BRPI0516894-5A priority patent/BRPI0516894A/pt
Priority to JP2007538233A priority patent/JP5364266B2/ja
Priority to EP05803045A priority patent/EP1815250A4/fr
Publication of WO2006047869A1 publication Critical patent/WO2006047869A1/fr
Priority to US11/743,058 priority patent/US8475735B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements

Definitions

  • the invention relates to the field of iinmunodiagnostic test systems, kits, and devices, and more particularly to a disposable immunodiagnostic test system for testing for the presence of marker proteins in a liquid sample analyte.
  • test devices may have a dipstick, a flow-through, and/or a lateral flow format.
  • test device may provide quicker and more accurate test results, that may not require the purchase of additional specialized equipment nor the supplemental training of already highly qualified testing personnel, and/or that may enable a single analyte sample to be tested on a substantially contemporaneous basis for the presence of any of a plurality -
  • an iitimunodiagnostic test system kit and/or device (which may, hereinafter, simply be referred to as an "immunodiagnostic test system") that is effective and simple to use, and may be quickly administered.
  • test system may be manufactured and/or assembled in the field and/or in a manufacturing facility that is specifically designed for that purpose. There is also a need for such a system that might also involve lower production and packaging costs.
  • test system may be selectively adaptable to provide either qualitative and/or quantitative results, depending on user preferences and/or the nature of the test to be conducted.
  • test systems has heretofore been substantially necessitated by the fact that such systems have typically been primarily composed of materials (such as plastic) that cannot be safely burned or incinerated without generating harmful and/or toxic fumes.
  • materials such as plastic
  • the disposal of test systems in landfills has also typically involved additional transportation and disposal costs and efforts.
  • field workers have been required to carry portable waste containers suited to securely transporting and disposing of such potentially contaminated test systems.
  • Such waste procedures may have involved sterile glassware, plastic ware, laboratory ware, and the like, as well as correspondingly stringent sterilizing and handling regimes. Accordingly, there is a continuing and acutely felt need for a test system that might be readily disposed of in a simple yet ecologically responsible manner, such as, for example, by incineration over an open fire.
  • test system may be selectively adaptable to detect for viral, fungal, bacterial, and/or vector induced infections, any or all of these tests possibly being performed using a single sample.
  • test system that provides visually discernable test results and/or results within a relatively short period of time, such as, for example, within sixty to ninety seconds. Accordingly, it is an object of the invention to obviate, mitigate, and/or address one or more of the above mentioned needs, shortcomings and/or disadvantages associated with the prior art.
  • the test system includes a substantially planar passage layer comprised of a first material having a substantially non-porous structure that is shaped so as to define at least one aperture therethrough.
  • the test system also includes a protein layer comprised of a second material that is adapted to enable, in an operative configuration, substantial immobilization of combinable proteins thereon.
  • the protein layer has a substantially porous structure so as to enable a portion of the liquid sample analyte to pass substantially therethrough.
  • the protein layer is in intimate contacting relation with the passage layer so as to define an active surface area on the protein layer that is substantially adjacent to, and substantially aligned with, the aperture of the passage layer.
  • the test system also includes an absorbent layer comprised of a third material that enables absorption of at least a portion of the liquid sample analyte.
  • the absorbent layer is in intimate contacting relation with the protein layer.
  • the combinable proteins are substantially immobilized on the protein layer as aforesaid, and the liquid sample analyte is introduced onto the protein layer through the at least one aperture of the passage layer.
  • the marker proteins are bound to the combinable proteins and substantially immobilized relative to the protein layer.
  • at least a portion of the liquid sample analyte passes substantially through the protein layer.
  • the first material, the second material, and the third material are constructed of at least one combustible material that _ _
  • the test system may also preferably comprise a reagent that, in the positive result configuration, is operatively bound to the marker proteins that are substantially immobilized relative to the protein layer.
  • the reagent may comprise a visually tagging substance that operatively provides a colored indicium of the positive result configuration.
  • the reagent may comprise a protein enzyme conjugate substance.
  • the test system may preferably further comprise an enzyme substrate substance that is operatively bound to the protein enzyme conjugate substance in the positive result configuration, and that may preferably operatively display a colored indicium in the positive result configuration.
  • At least a visible portion of the active surface area may be viewable through the aperture of the passage layer.
  • the test system may preferably further comprise at least one sealant substantially juxtaposed between the passage layer and the protein layer, and between the protein layer and the absorbent layer.
  • the visible portion of the active surface area may preferably comprise a first test surface area, with the combinable proteins preferably being substantially immobilized thereon in the operative -
  • the visible portion of the active surface area may preferably further comprise a procedural control surface area.
  • the procedural control surface area may preferably be adapted to display a control reading both in the positive result configuration and in the negative result configuration, so as to operatively confirm that the test system has been used properly.
  • the test system may preferably further comprise a housing substantially encapsulating the passage layer, the protein layer, and the absorbent layer.
  • a lower housing portion of the housing is in intimate contacting relation with the absorbent layer.
  • An upper housing portion of the housing is in intimate contacting relation with the passage layer.
  • the upper housing portion is shaped so as to define at least one housing aperture therethrough.
  • the housing aperture is substantially aligned in operative fluid communicating relation with the at least one aperture of the passage layer.
  • the housing may preferably be constructed of the aforesaid at least one combustible material.
  • the housing may preferably be comprised of a housing material having a substantially non-porous housing structure.
  • At least one sealant may preferably be substantially juxtaposed between the upper housing portion and the passage layer, and between the lower housing portion and the absorbent layer.
  • the housing may preferably comprise an exterior surface portion with at least one labeling indicium marked thereon.
  • the exterior surface portion may preferably be provided on the upper housing portion.
  • the combinable proteins may preferably, but not necessarily, comprise proteins adapted to be bound to fungal marker proteins, viral marker proteins, bacterial marker proteins, vector-induced marker proteins, plant marker proteins, and/or native proteins biosynthesizable by substantially healthy cells in at least one of the liquid sample analyte and a species furnishing same.
  • the visible portion of the active surface area may preferably further comprise a second test surface area. In the operative configuration, second combinable proteins are substantially immobilized on the second test surface area. In the positive result configuration, the marker proteins are bound to the second combinable proteins and substantially immobilized relative to the protein layer.
  • the visible portion of the active surface area may preferably further comprise a supplemental first test surface area and a supplemental second test surface area.
  • the combinable proteins are preferably, but not necessarily, substantially immobilized on each of the first test surface area and the supplemental first test surface area.
  • the second combinable proteins are preferably, but not — —
  • a substantially higher concentration of the combinable proteins are substantially immobilized on the supplemental first test surface area relative to a concentration of the combinable proteins on the first test surface area.
  • the first test surface area and the supplemental first test surface area may together preferably, but not necessarily, notionally define a substantially planar first test ring, with each of the first test surface area and the supplemental first test surface area notionally situated therewithin.
  • the second test surface area and the supplemental second test surface area may together preferably, but not necessarily, notionally define a substantially planar second test ring, with each of the second test surface area and the supplemental second test surface area notionally situated therewithin.
  • the second test ring may preferably, but not necessarily, substantially circumscribe the first test ring.
  • the first test ring may preferably, but not necessarily, substantially circumscribe the procedural control surface area.
  • the at least one aperture of the passage layer may preferably, but not necessarily, comprise at least two apertures.
  • An upper surface of the passage layer may preferably, but not necessarily, be shaped so as to define a _
  • an upper surface of the protein layer may preferably, but not necessarily, be shaped so as to define a concave portion.
  • the concave portion is preferably, but not necessarily, substantially adjacent to the visible portion of the active surface area and substantially aligned with the aperture of the passage layer.
  • Figure IA is top front left perspective view of one preferred embodiment of a disposable immunodiagnostic test system according to the invention.
  • Figure IB is a top front left perspective view of the test system of Figure IA, shown in an unsealed and exploded configuration with substantially aligning portions thereof shown in phantom outline;
  • Figure 2A is a top front left perspective view of another preferred embodiment of a test system according to the invention that includes a housing;
  • Figure 2B is a top front left perspective view of the test system of Figure 2A, shown in the unsealed and exploded configuration;
  • Figure 2C is an enlarged view of encircled area 2C of Figure 3, which is discussed hereinbelow;
  • Figure 2D is a top front left perspective view of a different preferred embodiment of a test system according to the invention that includes a plurality of passage layer apertures;
  • Figure 2E is a top front left perspective view of the test system of Figure 2D, shown in the unsealed and exploded configuration;
  • Figure 2F is an enlarged view, similar to Figure 2C, of the test system shown in Figure 2D;
  • Figure 3 is a cross-sectional view of the test system of Figure 2A taken along sight line 3-3;
  • Figure 4A is a top plan view of a further preferred embodiment of the test system according to the invention which is similar to that shown in Figure 2A; -
  • Figure 4B is a top plan view of the test system of Figure 2A;
  • Figure 4C is a top plan view of a still further preferred embodiment of the test system according to the invention which is similar to that shown in Figure 2A;
  • Figure 4D is a top plan view of the test system of Figure 2D, showing the upper housing portion and the passage layer;
  • Figure 4E is a top plan view of the test system of Figure 2D, showing the protein layer, with the housing and passage layer apertures shown in phantom outline;
  • Figure 5A is a top front left perspective view of still another embodiment of the test system according to the invention, shown in a partially unsealed and exploded configuration;
  • Figure 5B is a top front left perspective view of the test system of Figure 5A;
  • Figure 6 is a top front left perspective view of a portion of yet another embodiment according to the invention, depicting a plurality of frangible test systems, each similar to that shown in Figure 2A;
  • Figure 7 is a top front left perspective view of a portion of a yet further embodiment according to the invention, depicting a plurality of frangible test systems, each similar to that shown in Figure 2B.
  • FIG. IA, IB, 5A and 5B of the drawings there is shown a preferred embodiment of a disposable immunodiagnostic test system 70, according to the invention, for testing for the presence of marker proteins in - -
  • test system 70 includes a combined testing subassembly 50 and a housing 60.
  • test system 70 may simply include the combined testing subassembly 50, without the housing 60.
  • the combined testing subassembly 50 will be seen to include a substantially planar passage layer 12, a protein layer 14, and an absorbent layer 16, each of which is preferably constructed of a combustible material that produces non-toxic by-products upon incineration. • For this reason, among others, the combined testing subassembly 50 may be easily disposed of in an environmentally responsible manner, such as, for example, by incineration over an open flame.
  • the passage layer 12 is substantially planar and has an aperture 24 therethrough that is defined by a corresponding inner edge 26 of the passage layer 12. While the preferred embodiment shown in Figures IA, IB, 5A and 5B has a single aperture 24 through the passage layer 12, the passage layers of other embodiments (see, for example, Figures 2D through 2F which are discussed in further detail hereinbelow) may be provided with more than one aperture 24.
  • the passage layer 12 has a substantially non-porous structure, such that it will preferably have a substantially impermeable, non-sponge, and unwoven nature.
  • the passage layer 12 may preferably, but not necessarily, be constructed of a densely packed paper material, such as cardboard. Other relatively rigid materials, such as, for example, tree bark and/or packed leaf materials, may also be used in the construction of the passage layer 12 according to the invention. Thus, whether as a result of its preferably densely packed nature, the inherent - -
  • the passage layer 12 preferably provides a measure of rigidity to the test system 70.
  • the passage layer 12 is preferably, though not necessarily, between about 0.2 and 10 millimeters in thickness, with an even more preferred thickness being substantially within the range of between about 2 and 4 millimeters.
  • the protein layer 14 is in intimate contacting relation with the passage layer 12.
  • the protein layer 14 has an active surface area 30 that is substantially adjacent to said aperture 24 of said passage layer 12, and substantially aligned therewith (as indicated generally by phantom line "A" in Figure IB) .
  • at least a portion 31 of the active surface area 30 is preferably visible through the aperture 24.
  • the protein layer 14 may preferably, though not necessarily, be constructed from nitrocellulose, nylon, and/or acetate, and indeed from any such other material upon which reactant and/or combinable proteins might be bound or substantially immobilized. It is thought, though not essential to the working of the test system 70, that nitrocellulose is an effective protein-binding material that might be used in the protein layer 14. Suitable commercially available nitrocellulose membranes may be cast on a supporting thin paper backing and used in the protein layer 14 according to a preferred embodiment the present invention.
  • the protein layer 14 is preferably, though not necessarily, no greater than about 5 millimeters in thickness, with an even more preferred thickness being substantially within the range of between about 0.5 and 2.0 millimeters.
  • the protein layer 14 has a substantially porous structure, meaning that it 'is preferably provided with a plurality of pores (not shown) therethrough.
  • nitrocellulose membranes and some of the other preferred protein layer 14 materials it is now believed, though not essential to the working of the test system 70, that the provision of larger sized pores in the protein layer 14 will afford correspondingly lower protein binding capabilities and/or capacities.
  • a protein layer 14 having lower protein binding capabilities may lower the sensitivity of any test performed using the system 70.
  • a nitrocellulose protein layer 14 will preferably, though not necessarily, have pore sizes between about 0.1 microns and 25 microns in diameter, with an even more preferred diametrical size being substantially within the range of between about 0.4 and 2.0 microns. It is believed that protein layers 14 having pores (not shown) that are sized substantially within the aforesaid range may afford an improved protein binding capacity.
  • the absorbent layer 16 is in intimate contacting relation with the passage layer 12.
  • the absorbent layer 16 is constructed of an absorbent material that is preferably adapted, depending on the nature of the test to be performed, to take in or absorb at least a portion (more preferably, an excess portion) of the liquid sample analyte that is to be tested.
  • the absorbent layer 16 may preferably be formed from a sponge material, or indeed any other material capable of taking in or absorbing at least a portion of the liquid sample analyte (not shown) .
  • the absorbent layer 16 may be constructed from a paper towel and/or an acetate material.
  • the absorbent layer 16 is preferably, though not necessarily, between about 1 and 50 millimeters in thickness, with an even more preferred thickness being substantially within the range of between - -
  • the absorbent layer 16 will be adapted so that it might absorb and retain three times, or more, of the volume of the liquid sample analyte that is to be administered during a single test.
  • the absorbent layer 16 is in intimate contacting relation with the protein layer 14, and the protein layer 14 is in intimate contacting relation with the passage layer 12.
  • the passage layer 12 and the protein layer 14 may be held together in the aforesaid intimate contacting relation with the aid of a sealant (not shown) that is substantially juxtaposed therebetween.
  • the protein layer 14 and the passage layer 16 may preferably be held together in the aforesaid intimate contacting relation with the aid of the same or a different sealant (not shown) that is substantially juxtaposed therebetween.
  • Suitable sealants according to the invention may preferably, but not necessarily, include glue and other adhesives, as well as the use of stapling, stitching, and thermal and/or ultrasound sealing methodologies, or indeed any other material or process that is suitable to ensure that the layers 12, 14, 16 are substantially maintained in the aforesaid intimate contacting relation with one another. It is contemplated that, for ease of manufacture, a conventional thermal sealer or glue intended for domestic use may suffice to provide sufficient sealing properties according to the invention.
  • the combined testing subassembly 50 may preferably also include a subassembly peripheral sealing 34.
  • the subassembly peripheral sealing 34 in a preferred embodiment of the test system 70 may securely engage peripheral edge portions of each of the layers 12, 14, 16.
  • the subassembly peripheral sealing 34 may be constructed of the same or a yet different sealant as that which is discussed hereinabove.
  • the subassembly peripheral sealing 34 may consist of an adhesive material that may be adhered to the peripheral edge portions of the layers 12, 14, 16.
  • the subassembly peripheral sealing 34 may alternately be constructed of any material or indeed in a form that provides physical compression of the layers 12, 14, 16 (possibly substantially adjacent to their peripheral edge portions) to ensure that they are maintained in intimate contacting relation with one another.
  • the subassembly peripheral sealing 34 may consist of a clamping member (not shown) that engages the peripheral edge portion of the passage layer 12 and the absorbent layer 16 so as to apply a compressive force to all three layers 12, 14, 16 in intimate contacting relation with one another.
  • the housing 60 substantially encapsulates the passage layer 12, the protein layer 14, and the absorbent layer 16, as they may together be preferably, but not necessarily, assembled to form the combined testing subassembly 50.
  • the housing 60 may preferably include an upper housing portion 10 and a lower housing portion 18.
  • the upper housing portion 10 and the lower housing portion 18 may be preferably, but not necessarily, in intimate contacting relation with the passage layer 12 and the absorbent layer 16 respectively.
  • the upper housing portion 10 and the passage layer 12 may be held together in the aforesaid intimate contacting relation with the aid of the same or a different sealant (not shown) as that aforesaid, which sealant is substantially juxtaposed -
  • the lower housing portion 18 and the absorbent layer 16 may preferably be held together in the aforesaid intimate contacting relation with the aid of the same or a still different sealant (not shown) that is substantially juxtaposed therebetween.
  • the housing 60 may preferably be further provided with housing edge portions 36 that are substantially contiguous with one or more peripheral edges of each of the upper and lower housing portions 10, 18.
  • the housing edge portion 36 in a preferred embodiment of the test system 70 may securely engage peripheral edge portions 34 of the combined testing subassembly 50 (as shown in Figure 5B) , and/or it may engage the peripheral edge portions of each of the layers 12, 14, 16 (as shown in Figures 2A, 2D and 3, and discussed in further detail hereinbelow) .
  • the housing edge portion 36 may be constructed of the same or a yet different sealant as that which is discussed hereinabove, including any of the alternate sealant materials, methodologies, and/or forms that are mentioned hereinabove with reference to the subassembly peripheral sealing 34, preferably so as to maintain the combined testing subassembly 50 in intimate contacting relation with the housing 60.
  • the upper housing portion 10 is provided with a housing aperture 20 therethrough that is defined by a corresponding inner edge 22 of the upper housing portion 10.
  • the housing 60 is preferably constructed from substantially non-porous materials, meaning ones that are preferably substantially impermeable, and/or of a non- absorbing and/or unwoven construction.
  • All portions of the housing 60 are preferably constructed of materials that produce non-toxic by-products upon incineration, so as to better ensure that the test system 70 might be disposed of in an environmentally responsible manner, such as, for example, by combustion.
  • Paper is one preferred material that may be suitable for the construction of the housing 60.
  • Other like materials may also be used for the housing 60 according to the invention, and such materials might include cloth, nylon, silk, and/or biodegradable membranes.
  • Each of the upper and lower housing portions 10, 18 is preferably, though not necessarily, between about 0.1 and 3 millimeters in thickness, with an even more preferred thickness being substantially within the range of between about 0.2 and 0.4 millimeters.
  • the dimensions of a single test system 70 adapted for the testing of a single liquid analyte sample will be substantially in the order of about 20mm x 20mm x 10mm.
  • the upper housing portion 10 of the housing 60 preferably includes an exterior surface portion 46 with labeling indicia 11 marked thereon.
  • the labeling indicia 11 may be visible to the unaided human eye, and may include sequentially numbered barcode indicia 13 and/or text indicia 15.
  • the labeling indicia 60 may alternately be directly marked (not shown) on an exterior surface portion of the passage layer 12.
  • the labeling indicia 11 may be marked on the exterior surface portion by way of printing, adhering or being written.
  • Sequentially numbered barcode indicia 13 may preferably, but not necessarily, be provided to enable the tracking of each test system 70 and for other purposes, including, for example, - -
  • text indicia 15 may include information and data about the disposable immunodiagnostic test system 70 and its intended uses, such as, for ⁇ example, the name of the intended test, expiration dates, instructions, storage conditions, disposal instructions, and/or the like. It is to be further appreciated that the labeling indicia 11 may also consist of color coding (not shown) to identify each different the type of specific test system 70.
  • the test system 70 may be assembled by preferably, but not necessarily, inserting the combined testing subassembly 50 in the hollow housing 60.
  • the housing aperture 20 may preferably be in substantially vertical registration with the underlying aperture 24 in the passage layer 12.
  • the housing 60 may thereafter preferably be sealed at each of its open ends with the housing edge portion 36.
  • the material from which the housing edge portion 36 is formed may or may not be the same sealant material as that used for the subassembly peripheral sealing 34.
  • the disposable immunodiagnostic test system 70 (as best seen in Figure 5B) may preferably, but not necessarily, be completely assembled.
  • FIGs 2A through 4E depict alternate preferred embodiments of the test system 70 wherein, as is the case with all of the drawings, similar reference numerals have been used to designate like elements of the present invention, where possible, in the various views for ease of reference.
  • the embodiment of the test system 70 that is shown in Figures 2A, 2B, 2C, and 3 is in most respects identical to that which has been discussed hereinabove, save that the upper and lower housing layers 10, 18 each consist of substantially planar and substantially more discrete layer portions that the more pillow-shaped embodiment that is shown in Figures 5A and 5B.
  • the housing aperture 20 is substantially aligned with the passage layer aperture 24 (as generally indicated by phantom lines "B" in Figure 2B) .
  • the an upper surface of the protein layer 14 may preferably, but not necessarily, be shaped so as to define a concave portion 58 that is substantially adjacent to, and substantially aligned with, the inner edges 22, 26 of the upper housing portion 10 and the passage layer 12.
  • the passage layer 12 is provided with first apertures 24a, second apertures 24b, and a control aperture 24c therethrough.
  • the an upper surface of the passage layer 12 may preferably, but not necessarily, be shaped so as to define a concave portion 56 that is substantially adjacent to, and substantially aligned with, the inner edge 22 of the upper housing portion 10.
  • the disposable immunodiagnostic test system 70 may be provided in a multiple test format.
  • individual test systems 70 may be arranged in side-by-side removably connected and/or frangible relation by means of tearable housing perforations 38 that may be torn by an end user (not shown) , who might determine the number of test systems 70 that are required for any particular or intended use.
  • the individual test systems 70 that are shown in Figure 6 may each substantially correspond with those shown elsewhere in Figures 2A through 4E.
  • the individual test systems 70 that are shown in Figure 7 may each substantially correspond with those shown in Figures 5A and 5B.
  • the various preferred embo.diments of the test system 70 that are shown in the drawings are each preferably, but not ' necessarily, adapted to test for the presence of marker proteins in a liquid sample analyte (not shown) .
  • the liquid sample analyte is the sample that is intended to be tested by. the system 70, which sample may or may not contain the sought-after marker proteins. That is, the liquid sample analyte is the substance or constituent being tested or undergoing analysis, and includes, for example, liquid sample matrices, serums, plasmas, perspiration, urine samples, and/or other aqueous extracts that contain body substances in which tissue cells are embedded and/or suspended.
  • test system 70 may preferably be adapted to test for the presence of marker proteins from a broad class, including those of a biological, agricultural, veterinary, and/or environmental origin.
  • the system 70 may be used, in conjunction with aqueous plant or leaf extracts, to detect for the presence of various diseases in banana plants, such as, for example, the banana bract mosaic virus (a common banana plant disease in areas such as India, the Philippines and Sri Lanka) , and/or the abaca mosaic virus (a common banana plant disease in the Philippines) .
  • banana bract mosaic virus a common banana plant disease in areas such as India, the Philippines and Sri Lanka
  • abaca mosaic virus a common banana plant disease in the Philippines
  • the system 70 may be used to detect for the presence of various diseases in animals and/or household pets, such as dogs or cats.
  • the system 70 might be used to detect for the presence of heartworm disease and/or other diseases, such as, for example, leishmaniasis, parvo viral infections, and/or lyme disease.
  • the system 70 may preferably, but not necessarily, also be used to detect for the presence of various environmental pollutants, such as, for example, gasoline additives like methyl tertiary butyl ether.
  • gasoline additives like methyl tertiary butyl ether.
  • gasoline additives may typically be used to benefit air quality by reducing automobile emissions, they may also problematically find their way to groundwater supplies that may ultimately be destined for human consumption.
  • the test system 70 may also be used to detect for the presence of various diseases common to humans that may be caused by any number of pathogens.
  • the test system 70 of the present invention may be capable of use to simultaneously detect for the presence of causative agents associated with a number of diseases, such as cardiovascular diseases.
  • the causative agents may include a wide number of differing pathogens, such as, for example, agents of viral, fungal and/or bacterial origin.
  • the system 70 might also be used to test for the presence of antibodies to healthy cell markers, such as, for example, the . protein myosin which is found in heart muscles, and/or to any of the causative agents listed hereinabove.
  • test system 70 The particular applications of the test system 70 which are discussed herein are merely intended to serve as examples of the testing capabilities of the invention, and are not intended to limit the potential applications of the test system 70 and its varied uses in conjunction with various liquid sample analytes.
  • protein layer 14 of the test device Operatively, the protein layer 14 of the test device
  • combinable proteins (not shown) bound to and/or substantially immobilized thereon.
  • the combinable proteins may be stuck onto a surface of the protein layer 14 and/or they might be substantially embedded therein. Indeed, a wide variety of different manners of binding and/or affixation of the combinable proteins to the protein layer 14 will preferably fall within the scope of the invention.
  • the combinable proteins that are operatively bound to the protein layer 14 of the test system 70 may preferably be specifically selected to correspond with the test to be conducted and/or so as to ensure binding with the sought-after marker proteins that may be present in the particular liquid sample analyte that is to be tested.
  • the test system 70 is intended to test for the presence of HIV 1, then combinable proteins that are particularly well suited to bind with HIV 1 and/or its marker proteins might be substantially immobilized on the protein layer 14.
  • the test system 70 is to be used to test for Hepatitis C, then combinable proteins that are particularly well suited to bind with Hepatitis C and/or its marker proteins might be substantially immobilized on the protein layer 14.
  • test system 70 may preferably, but not necessarily, be used to simultaneously detect for the presence of causative agents for a wide number of diseases, including, for example, agents of viral, fungal and/or - -
  • combinable proteins may comprise proteins which are adapted to be bound to fungal marker proteins, viral marker proteins, bacterial marker proteins, and/or vector-induced marker proteins, as may be present in the tested liquid sample analyte.
  • the protein layer 14 is a "reaction zone" of the test system 70.
  • the combinable proteins will preferably be substantially immobilized on the protein layer 14, and more preferably, on the active surface area 30 and visible portion 31 of the protein layer 14.
  • the nitrocellulose or other protein layer 14 of the test system 70 may preferably be provided to the end user (not shown) with the combinable proteins already substantially immobilized thereon.
  • the combinable proteins may also preferably be immobilized on the protein layer 14 at, or near, the time of testing.
  • the combinable proteins will preferably be those to which the sought-after marker proteins, if present in the tested subject liquid sample analyte, will affix such as by sticking or binding.
  • the combinable proteins may preferably be immobilized directly onto the protein layer 14 in the general vicinity of the active surface area 30, and more preferably in the visible portion 31 of the active surface area 30.
  • the combinable proteins may be immobilized in the visible portion 31 of the active surface area 30 in any desired pattern, shape or design, even after the test system
  • HIV 1 combinable proteins might preferably be immobilized on the active surface area 30 in the visually discernable form of a numeral "1" (not shown) , and likewise, Hepatitis C combinable proteins might preferably be immobilized thereon in the form of the letter "C".
  • any such other format might be used to suit the user and/or manufacturer of the test system 70.
  • combinable proteins may be substantially immobilized on the protein layer 14 by applying and/or depositing a combinable protein solution (not shown) onto the active surface area 30 of the protein layer 14, such as, for example, by ink jet spraying, by physically using a pipette, and/or by touching the combinable protein solution onto the designated area of the nitrocellulose membrane or other protein layer 14, such that the combinable proteins might then be absorbed onto the protein layer 14 by suction and/or capillary action.
  • a combinable protein solution not shown
  • combinable proteins for the detection of a plurality of different marker proteins in the liquid sample analyte may preferably be selected and/or immobilized, in any useful pattern on the protein layer 14, substantially in the region of the active surface area 30.
  • marker proteins in the liquid sample analyte may be permitted, in some of the contemplated uses discussed hereinbelow, to become substantially immobilized relative to the protein layer 14.
  • the active surface area 30 is preferably viewable, by the user, through the housing aperture 20 and the aperture 24 in the passage layer.
  • the active surface area 30 includes a first test surface area 32 and a procedural control surface area 28.
  • the combinable proteins immobilized on the protein layer 14 are substantially immobilized on the first test surface area 32.
  • the procedural control surface area 28 is adapted to display a control reading both in a positive result configuration (as shown in Figures 4A and 4B) and in a negative result configuration (not shown) of the test system 70, so as to preferably confirm that it has been used, handled and/or stored properly.
  • a control reading may preferably be generated in and displayed from the procedural control surface area 28.
  • the control reading may preferably, but not necessarily, take the form of a color or other indication that may correspond to a pattern of the combinable proteins that are operatively immobilized on the active surface area 30 of the protein layer 14, as discussed above.
  • the absence of a control reading in the procedural control surface area 28 might preferably indicate that any test performed using the system 70 may be invalid. It should be appreciated that, while the procedural control surface area 28 need not, strictly speaking, be present in the test system 70 according to the invention, it is preferably present. If a single type of qualitative marker protein test is to be performed using the system 70, the procedural control surface area 28 may preferably, but not necessarily, be -
  • the procedural control surface area 28 may preferably, but not necessarily, be located in a substantially central location of the active surface area 30, as shown in Figure 4B.
  • the active surface area 30 may preferably further comprise a supplemental first test surface area 32a.
  • the same combinable proteins are preferably operatively immobilized on both the first test surface area 32 and the supplemental first test surface area 32a, albeit in preferably, though not necessarily, different concentrations. For example, a substantially higher concentration of combinable proteins may be substantially immobilized on the supplemental first test area 32a relative to a concentration of the combinable proteins on the first test surface area 32.
  • the procedural control surface area 28 may preferably, but not necessarily, be located in a substantially central location of the active surface area 30.
  • the active surface area 30 may additionally include a second test surface area 33, with a second set of different combinable proteins
  • the second set of combinable proteins may preferably be selected and/or adapted to detect for the presence of different marker proteins than those of the (first set of) combinable proteins. Likewise, the second set of combinable proteins may immobilized in any useful pattern on the protein layer 14. - -
  • the active surface area 30 may also include a supplemental second test surface 33a.
  • the same combinable proteins are preferably operatively immobilized on both the second test surface area 33 and the supplemental second test surface area 33a, albeit in preferably, though not necessarily, different concentrations.
  • a substantially higher concentration of combinable proteins may be substantially immobilized on the supplemental second test area 33a relative to a concentration of the combinable proteins on the second test surface area 33.
  • first test surface area 32 and the supplemental first test surface area 32a may preferably, but not necessarily, together notionally define a substantially planar first test ring 40.
  • Each of the first test surface area 32 and the supplemental first test surface area 32a are preferably, but not necessarily, notionally situated therewithin.
  • the ' procedural control surface area 28 may preferably, but not necessarily, be substantially circumscribed within the first test ring 40.
  • the second test surface area 33 and the supplemental second test surface area 33a may also preferably, but not necessarily, together notionally define a substantially planar second test ring 42.
  • Each of the second test surface area 33 and the supplemental second test surface area 33a are preferably, but not necessarily, notionally situated therewithin.
  • the second test ring 42 may preferably, but not necessarily, substantially circumscribe the first test ring 40.
  • first test surface area 32, the supplemental first test surface area 32a, the second test surface area 33, the supplemental second test surface area 33a, and the procedural control surface area 28 may together notionally define various configurations, such as, for example, various other concentric and/or non-concentric geometric shapes.
  • other geometric shapes may be formed that may, for example, comprise differing a multiple number of concentric shapes.
  • the first and/or the second test surface area 32, 33 may consist of mimicry surface areas.
  • the combinable proteins substantially immobilized on the first and/or second test surface areas 32, 33 may be native proteins that are biosynthesizable by substantially healthy cells in the liquid sample analyte and/or a species furnishing same.
  • the passage layer 12 is formed with first and second apertures 24a, 24b, and a control aperture 24c therethrough.
  • first apertures 24a are substantially aligned "A" with the first test ring 40
  • second apertures 24b are substantially aligned with the second test ring 42
  • control aperture 24c is substantially aligned with the procedural control surface area 28 on the protein layer 14.
  • a first drop of wash buffer is preferably added to the test system 70 through the housing aperture 20 of the upper housing portion 10, to wet the visible portion 31 of the active surface area 30 on the protein layer 14, and is allowed to adsorb.
  • the wash buffer will preferably, but not necessarily, act as a blocker for any areas on the active surface area 30 where no combinable proteins have been immobilized, so as to provide an inactive protein wash bound area 44 (as seen in, for example, Figure 4A and 4B) , thus preferably preventing the indiscriminate affixation of marker and/or other proteins from the liquid sample analyte thereon.
  • the liquid sample analyte may preferably then be introduced, using a pipette or the like, through the housing aperture 20 of the test system 70.
  • the housing aperture 20 is in operative fluid communication with the passage layer aperture 24, such that the liquid sample analyte may preferably be deposited onto the active surface area 30 of protein layer 14 through the at least one aperture 24 of the passage layer 12.
  • the liquid sample analyte may be operatively introduced through the housing aperture 20 in a quantity that is preferably, though not necessarily, sufficient to cover the visible portion 31.
  • test system 70 of the present invention tests for the presence of marker proteins in the liquid sample analyte.
  • system 70 will preferably reveal that the sought-after marker proteins are actually present in the liquid sample analyte.
  • one or more marker proteins from the liquid sample analyte will preferably be bound to the combinable proteins and substantially immobilized relative to active surface area 30 of the protein layer 14.
  • the first and second test surface areas 32, 33 may preferably have the first and second marker proteins respectively bound thereto in the positive result configuration.
  • the combinable proteins comprise native proteins substantially immobilized on the mimicry surface area
  • the marker proteins may preferably be bound to the native proteins and substantially immobilized relative to the protein layer.
  • the use of the test system 70 will preferably not reveal the presence of any of the marker proteins in the liquid sample analyte.
  • the negative result configuration (not shown), at least a portion and preferably most and/or substantially all of the liquid sample analyte will pass substantially through the protein layer 14, without affixing to any of the combinable proteins immobilized thereon.
  • a portion of the liquid sample analyte may preferably traverse - -
  • a sufficient quantity of the liquid sample analyte will be introduced onto the protein layer 14 so as to ensure that any sought-after marker proteins which may be contained therein become substantially immobilized relative to the protein layer 14 (in a positive result configuration) or not (in a negative result configuration) .
  • the aforesaid substantially porous structure of the protein layer 14 preferably enables a portion of the liquid sample analyte to pass therethrough.
  • liquid sample analytes that contain particulate matter (such as whole blood) that are lipaemic, and/or that may require further clarification or amplification may not filter through pore sizes smaller than about 5 to 6 microns in the protein layer 14, such liquid sample analytes may preferably, but not necessarily, be clarified and/or broken down prior to testing.
  • Liquid sample analytes that may be tested without further clarification and/or amplification may preferably include, for example, serum, plasma, urine, perspiration and/or exudates.
  • Other aqueous extracts that may preferably be clarified by filtration and/or centrifugation may also form a part of the analyte to be tested using with test system 70.
  • a drop or other necessary quantity of a reagent may preferably then be added, in a preferred quantity that covers the visible portion 31 of the active surface area 30.
  • the reagent is particularly selected and/or adapted to operatively bind to any marker proteins that may have been substantially immobilized relative to the protein layer 14 in the positive result configuration.
  • the reagent may preferably comprise a visually tagging substance that, when specifically bound to any marker proteins affixed to the combinable protein that are immobilized on the protein layer 14, provides colored indicia indicating and/or confirming that the test system 70 is in the positive result configuration.
  • the visually tagging substance may comprise any one or more of a variety of substances, such as, for example, a radioactive isotope substance, a fluorescent substance, a UV absorbing substance, and/or a colored substance.
  • the colored visually tagging substances may consist of a colloidal gold conjugate substance, a dyed latex bead substance, and/or the like.
  • amplifications by enzyme conjugates may be necessary for analytes in nanogram to femtogram quantities.
  • Situations where amplifications by enzyme conjugates may be preferable might include, for example, IgE detection in allergy diagnosis, and/or detection for drug abuse, industrial and environmental pollutants, diseases in plants, hormones, cancer markers, arthritis markers, and/or the like.
  • the aforesaid reagent may comprise a protein enzyme conjugate substance (not shown) .
  • the protein enzyme conjugate substance is particularly selected and/or adapted to operatively bind to any marker proteins that may have been substantially immobilized relative to the protein layer 14 in the positive result configuration.
  • wash buffer may then preferably be added to the active surface area 30 to preferably, but not necessarily, wash away any unbound material.
  • the wash buffer may be allowed to adsorb into the protein layer 14.
  • an enzyme substrate substance (not shown) may then be preferably added. Thereafter, the user will wait for a suitable period of time to elapse, possibly in the order of approximately 10 to 60 seconds, during which period the enzyme substrate substance will be afforded an opportunity to operatively bind to the protein enzyme conjugate substance in the positive result configuration.
  • the protein enzyme conjugate substance and the enzyme substrate substance are together selected and/or adapted to operatively display coloured indicia indicating and/or confirming that the test system 70 is in the positive result configuration. In this embodiment of the test system
  • an additional drop of wash buffer may preferably then be added through housing aperture 20, and allowed to traverse substantially vertically away from its point of entry into the test system 70 and through the multiple layers of the test system, as aforesaid, before the results are read.
  • All materials, possibly including any excess marker proteins, that do not become immobilized relative to the protein layer 14 by affixation (e.g., by sticking or binding) to the combinable proteins that are already immobilized thereon may preferably, though not necessarily, traverse through the protein layer 14 to be ultimately captured, trapped and/or absorbed by the absorbent layer 16.
  • a liquid sample analyte (not shown) may preferably be introduced onto the protein layer 14 through the at least one aperture 24 of - -
  • the liquid sample analyte passes through the protein layer 14, and subsequently into the absorbent layer 16.
  • the disposable immunodiagnostic test system 70 may preferably be allowed to dry, after which it may be disposed of in an ecologically responsible mode of disposal, such as, for example, by incineration.
  • the liquid sample analyte is permitted, in use, to traverse through the test system 70.
  • test system 70 should preferably be assembled in intimate contacting relation with one another, and/or in non-loose fitting relation, so as to provide the test system 70 with improved integrity. It is further believed, though not essential to the invention, that the test system 70 may function effectively so long as the assembled layers are positioned in sufficient intimate contacting relation to cause a liquid sample analyte added to traverse away from its point of entry into the test system 70 and substantially vertically therethrough, under the influence of gravity and/or another similar force.
  • the substantially contemporaneous testing of a single liquid sample analyte for the presence of multiple marker proteins, using a single test system 70 may offer significant advantages. These advantages may preferably include a quicker total administration time, and lower cost of materials, when compared to the corresponding administration of four or a like number of separate tests that may otherwise be required on multiple testing systems, along with corresponding controls.
  • Use of the test system 70 will preferably be simple to use and quick to administer and for provide quick and highly accurate and effective test results, without requiring the purchase of additional specialized equipment nor the supplemental training of already highly qualified testing personnel.
  • test system 70 may preferably be used in a clinical setting, at the point of care, and/or in the field.
  • the test system 70 preferably may be manufactured and/or assembled in the field and/or in a manufacturing facility that is specifically designed for that purpose, and as such, it preferably also involves lower production and packaging costs.
  • the test system 70 is preferably selectively adaptable to provide qualitative and/or quantitative results, depending on the user's preferences and/or the nature of the test to be conducted. _
  • the. test system 70 may preferably be readily disposed of in a simple yet ecologically responsible manner, such as, for example, by incineration over an open fire.
  • the test system 70 may preferably be selectively adaptable to detect for viral, fungal, bacterial, and/or vector induced infections.
  • the test system 70 preferably provides visually discernable test results and/or results within a relatively short period of time.
  • the housing 60 and/or the various layers 12, 14, 16 of the test system 70 may be configured in various geometric shapes, such as, for example, in a square, rectangular, circular, and/or spherical shapes.
  • the test system 70 may be provided with a plurality of test surface areas (not shown) apart from the first and second test surface areas 32, 33 which are described above.
  • the visible portion 31 of the active surface area 30 might further comprise a plurality of supplemental test surface areas that may, in combination, also be configured in various geometric shapes.
  • an upper surfaces of the passage and protein layers 12, 14 may be shaped so as to define their respective concave portions 56, 58, the passage and protein layers 12, 14 may also each- define respective convex, or such other shaped, portions as well.
  • the labeling indicia 11 may be marked on the upper housing portion 10 or on the passage layer 12 in ⁇ J O —
  • the units of the disposable immunodiagnostic test system may be arranged in "multiple packs", or in any such other removably connected or frangible relation that may be desired by the end user (i.e., other than in the representative side-by-side removably connected relation format shown in Figures 6 and 7) .
  • the disposable immunodiagnostic test system 70 may be assembled without an upper housing portion 10, and in such embodiments, it would be comprised of at least the passage layer 12 (possibly with certain labeling indicia
  • the protein layer 14, the absorbent layer 16, the lower housing portion 18, and the housing side portions 36 are marked on its exterior surface.
  • the lower housing portion 18 may be eliminated, such that the disposable immunodiagnostic test system 70 would then be comprised of at least the upper housing portion 10, the passage layer 12 (ensuring that the housing aperture 20 is aligned in substantial vertical registration with the aperture 24 in the passage layer 12), the protein layer 14, the absorbent layer 16, and the housing side portions 36.
  • test system 70 may sometimes hereinabove have been described as a rapid assay test in a flow through format, it may instead be constructed in a lateral flow format as well.
  • the test systems 70 discussed hereinabove are preferably disposable and cost-effective immunodiagnostic test systems that are utilizable for detection of one or more marker proteins in a liquid sample analyte or matrix.
  • the present invention may be used to test for multiple marker proteins in a single test, as may preferably be administered through the use of a single liquid sample analyte, there is preferably a reduced wait time before the results might be obtainable.
  • the present invention is contemplated to be used primarily as an immunodiagnostic system, it may also be manufactured for use in the detection of various marker proteins and such other materials as may be present in tissue culture fluids, plant extracts, seed extracts, soil extracts, and/or water and other aqueous extracts.
  • the disposable immunodiagnostic test system 70 may preferably be disposed of in an ecologically responsible and inexpensive manner, such as, for example, by incineration or burning in an open fire.
  • the disposable immunodiagnostic test system 70 may preferably have lower costs of production and disposal associated with it, in comparison to other analyte testing devices that may be presently available.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un système de tests immundiagnostiques jetables pour protéines marqueurs dans des analytes d'échantillons liquides. Ce système consiste à mettre en contact étroit une couche de passage, une couche protéique et une couche absorbante. La couche de passage est non poreuse et comporte une ouverture. La couche protéique est poreuse et permet opérationnellement l'immobilisation de protéines combinables, ainsi que le passage de l'analyte à travers ladite couche. La couche protéique comporte une surface de contact active alignée avec l'ouverture de la couche de passage. L'analyte est introduit opérationnellement sur la couche protéique par l'ouverture de la couche de passage. Dans les résultats positifs, les protéines marqueurs sont liées opérationnellement aux protéines combinables et immobilisées par rapport à la couche protéique. Dans les résultats négatifs, l'analyte traverse opérationnellement la couche protéique et il est absorbé par la couche absorbante. Le système selon l'invention peut également comprendre un logement. Ledit système est fabriqué à partir d'un matériau combustible qui produit des sous-produits non toxiques lorsqu'il est incinéré, ce qui permet une élimination responsable du point de vue écologique après usage diagnostique de ce système.
PCT/CA2005/001677 2004-11-01 2005-11-01 Systeme de tests immunodiagnostiques jetables WO2006047869A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AP2007004015A AP2007004015A0 (en) 2004-11-01 2005-11-01 Disposable immunodiagnostic test system
AU2005301045A AU2005301045B2 (en) 2004-11-01 2005-11-01 Disposable immunodiagnostic test system
CN200580045347.7A CN101133326B (zh) 2004-11-01 2005-11-01 易处理免疫诊断检测系统
CA002585695A CA2585695C (fr) 2004-11-01 2005-11-01 Systeme de tests immunodiagnostiques jetables
MX2007005180A MX2007005180A (es) 2004-11-01 2005-11-01 Sistema de prueba para inmunodiagnostico desechable.
BRPI0516894-5A BRPI0516894A (pt) 2004-11-01 2005-11-01 sistema de teste imunodiagnóstico descartável
JP2007538233A JP5364266B2 (ja) 2004-11-01 2005-11-01 ディスポーザブル免疫診断検査システム
EP05803045A EP1815250A4 (fr) 2004-11-01 2005-11-01 Systeme de tests immunodiagnostiques jetables
US11/743,058 US8475735B2 (en) 2004-11-01 2007-05-01 Disposable immunodiagnostic test system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62322404P 2004-11-01 2004-11-01
US60/623,224 2004-11-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/743,058 Continuation-In-Part US8475735B2 (en) 2004-11-01 2007-05-01 Disposable immunodiagnostic test system

Publications (1)

Publication Number Publication Date
WO2006047869A1 true WO2006047869A1 (fr) 2006-05-11

Family

ID=36318848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2005/001677 WO2006047869A1 (fr) 2004-11-01 2005-11-01 Systeme de tests immunodiagnostiques jetables

Country Status (10)

Country Link
EP (1) EP1815250A4 (fr)
JP (1) JP5364266B2 (fr)
CN (1) CN101133326B (fr)
AP (1) AP2007004015A0 (fr)
AU (1) AU2005301045B2 (fr)
BR (1) BRPI0516894A (fr)
CA (1) CA2585695C (fr)
MX (1) MX2007005180A (fr)
WO (1) WO2006047869A1 (fr)
ZA (1) ZA200704512B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022537A1 (fr) * 2008-08-26 2010-03-04 红电医学科技股份有限公司 Plaque de base de puce de test de fluide
WO2010031201A1 (fr) * 2008-09-16 2010-03-25 红电医学科技股份有限公司 Puce d’analyse de fluide à deux utilisations
US7964370B2 (en) 2008-10-17 2011-06-21 Actherm Inc Analytical strip and detecting method using the same
US8133718B2 (en) 2008-10-17 2012-03-13 Actherm Inc Analytical strip and detecting method using the same
US8367015B2 (en) 2009-03-23 2013-02-05 Actherm Inc Analytical strip and the manufacturing method thereof
US8372660B2 (en) 2008-10-09 2013-02-12 Actherm Inc Quantitative analyzing method

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110046451A (ko) * 2008-08-29 2011-05-04 액텀 아이엔씨. 분석 스트립
AU2013208289B2 (en) 2012-01-10 2016-08-11 Idexx Laboratories, Inc. Immunoassay test slide
CN105954276B (zh) * 2016-06-02 2018-12-21 上海丰能医药科技有限公司 一种智能健康检测装置及方法
EP3574318B1 (fr) * 2017-01-27 2020-12-09 Becton, Dickinson and Company Dispositif de dosage à écoulement vertical pour détecter la concentration de glucose dans un échantillon de fluide
KR102082898B1 (ko) * 2018-04-18 2020-02-28 가천대학교 산학협력단 병원균 검출을 위한 비색 검출 장치 및 그의 제조방법
CN108982832A (zh) * 2018-09-28 2018-12-11 蓝怡科技集团股份有限公司 一种免疫诊断用检测装置

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246339A (en) 1978-11-01 1981-01-20 Millipore Corporation Test device
WO1989011100A1 (fr) * 1988-05-10 1989-11-16 E.I. Du Pont De Nemours And Company Dispositif d'analyse et immunoanalyse
EP0295069B1 (fr) 1987-06-12 1992-08-26 Pall Corporation Dispositif d'épreuve diagnostique
WO1996021863A1 (fr) 1995-01-09 1996-07-18 Robert Chen Kit de dosage immunologique et procede de detection rapide d'anticorps diriges contre vih-1 et vih-2
GB2345133A (en) * 1998-12-24 2000-06-28 Hypoguard Limited Polyspecific antibody immunodiagnostic device
DE19859066A1 (de) 1998-12-22 2000-07-06 Engel Matthias Werner Testvorrichtung für Immunoassays

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185127A (en) * 1989-09-21 1993-02-09 Becton, Dickinson And Company Test device including flow control means
CA2035595A1 (fr) * 1990-04-12 1991-10-13 Carol A. Miller Appareil pour le dosage immunologique dote d'un fil comme element de controle
JP2640798B2 (ja) * 1992-07-10 1997-08-13 喜春 土屋 検尿用採尿容器及び検尿装置
JP3299330B2 (ja) * 1993-03-18 2002-07-08 持田製薬株式会社 簡易測定装置および方法
JPH08285849A (ja) * 1995-04-14 1996-11-01 Mochida Pharmaceut Co Ltd 簡易測定装置およびこれを用いる測定方法
US6316205B1 (en) * 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
CN1161612C (zh) * 2000-06-01 2004-08-11 松下电器产业株式会社 生物传感器及血液成分分析方法
DK2311934T3 (da) * 2001-09-06 2013-09-08 Rapid Micro Biosystems Inc Hurtig påvisning af replicerende celler
JP4286157B2 (ja) * 2003-01-21 2009-06-24 デンカ生研株式会社 メンブレンアッセイ法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4246339A (en) 1978-11-01 1981-01-20 Millipore Corporation Test device
EP0295069B1 (fr) 1987-06-12 1992-08-26 Pall Corporation Dispositif d'épreuve diagnostique
WO1989011100A1 (fr) * 1988-05-10 1989-11-16 E.I. Du Pont De Nemours And Company Dispositif d'analyse et immunoanalyse
WO1996021863A1 (fr) 1995-01-09 1996-07-18 Robert Chen Kit de dosage immunologique et procede de detection rapide d'anticorps diriges contre vih-1 et vih-2
DE19859066A1 (de) 1998-12-22 2000-07-06 Engel Matthias Werner Testvorrichtung für Immunoassays
GB2345133A (en) * 1998-12-24 2000-06-28 Hypoguard Limited Polyspecific antibody immunodiagnostic device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1815250A4

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022537A1 (fr) * 2008-08-26 2010-03-04 红电医学科技股份有限公司 Plaque de base de puce de test de fluide
WO2010031201A1 (fr) * 2008-09-16 2010-03-25 红电医学科技股份有限公司 Puce d’analyse de fluide à deux utilisations
US8372660B2 (en) 2008-10-09 2013-02-12 Actherm Inc Quantitative analyzing method
US7964370B2 (en) 2008-10-17 2011-06-21 Actherm Inc Analytical strip and detecting method using the same
US8133718B2 (en) 2008-10-17 2012-03-13 Actherm Inc Analytical strip and detecting method using the same
US8367015B2 (en) 2009-03-23 2013-02-05 Actherm Inc Analytical strip and the manufacturing method thereof

Also Published As

Publication number Publication date
EP1815250A1 (fr) 2007-08-08
MX2007005180A (es) 2007-11-08
JP2008518215A (ja) 2008-05-29
CN101133326A (zh) 2008-02-27
CN101133326B (zh) 2013-05-29
CA2585695A1 (fr) 2006-05-11
AP2007004015A0 (en) 2007-06-30
BRPI0516894A (pt) 2008-09-23
EP1815250A4 (fr) 2008-06-25
AU2005301045A1 (en) 2006-05-11
AU2005301045B2 (en) 2012-10-18
JP5364266B2 (ja) 2013-12-11
ZA200704512B (en) 2008-07-30
CA2585695C (fr) 2008-12-16

Similar Documents

Publication Publication Date Title
US8475735B2 (en) Disposable immunodiagnostic test system
CA2585695C (fr) Systeme de tests immunodiagnostiques jetables
CA2285048C (fr) Dispositif analytique pour tests a base de membranes
EP1696236B1 (fr) Dispositif de collecte pour analyse des fluides buccaux
CN202886374U (zh) 一个进行多个测试的设备
EP1824991B1 (fr) Dispositif et procede destines a detecter des analytes
AU2005221615B2 (en) Analyte collection and detection devices
US20030045001A1 (en) Immunochromatographic test strip with arcuate sample application zone for ease-of-use in the field
JPS63269056A (ja) 免疫検定装置、方法、およびキット
JP2530021B2 (ja) 比色指示試験装置
US20100304397A1 (en) Chromogenic test kit for detecting health conditions in saliva
AU769427B2 (en) Sample collection and testing system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007538233

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005180

Country of ref document: MX

Ref document number: 2585695

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11743058

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1888/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: AP/P/2007/004015

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 2005301045

Country of ref document: AU

Ref document number: 2005803045

Country of ref document: EP

Ref document number: 2007/04512

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2005301045

Country of ref document: AU

Date of ref document: 20051101

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005301045

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580045347.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005803045

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11743058

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0516894

Country of ref document: BR